Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4538-88 (TASUKI-88) Phase II Study in NSCLC and Gastric Cancer
jRCT2080225262Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), gastric cancer (GC) and esophagogastric junction cancer, sponsored by Ono Pharmaceutical. Started Jul 2020; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on jRCT2080225262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225262.